Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): In vitro and in vivo antiviral activity and mechanism of action

Journal of Antimicrobial Chemotherapy

Volumn 48, Issue 6, 2001, Pages 757-767

  Reefschlaeger, Juergen ^a   Bender, Wolfgang ^a   Hallenberger, Sabine ^a,b   Weber, Olaf ^b   Eckenberg, Peter ^a   Goldmann, Siegfried ^a   Haerter, Michael ^a   Buerger, Iris ^a,d   Trappe, Joerg ^c   Herrington, Janet A ^b   Haebich, Dieter ^a   Ruebsamen Waigmann, Helga ^a  

^a BAYER AG   (Germany)

^b BAYER CORPORATION   (United States)

^c Bayer SpA Italy   (Italy)

^d MILTENYI BIOTEC GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 2,2 DIMETHYL N (4(((5 (DIMETHYLAMINO) 1 NAPHTHYL)SULFONYL)AMINO)PHENYL)PROPANAMIDE; 3-HYDROXY-2,2-DIMETHYL-N-(4(((5-(DIMETHYLAMINO)-1-NAPHTHYL)SULFONYL)AMINO)PHENYL)PROPANAMIDE; ANTIVIRUS AGENT; NAPHTHALENESULFONIC ACID DERIVATIVE; VIRUS DNA;

ANIMAL; ANTIBIOTIC RESISTANCE; ARTICLE; CELL LINE; CELL STRAIN 3T3; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; DOSE RESPONSE; DRUG EFFECT; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MALE; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MOUSE; MOUSE MUTANT; VIROLOGY;

3T3 CELLS; ANIMAL; ANTIVIRAL AGENTS; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; HUMAN; MALE; MICE; MICE, SCID; MICROBIAL SENSITIVITY TESTS; NAPHTHALENESULFONATES;

EID: 0035656411     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/48.6.757     Document Type: Article

References (37)

1. Elion, G. B., Furman, P. A., Fyfe, J. A., De Miranda, P., Beauchamp, L. & Schaeffer, H. J. (1977). Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proceedings of the National Academy of Sciences, USA 74, 5716-20.
2. Derse, D., Cheng, Y.-C., Furman, P. A., St Clair, M. H. & Elion, G. B. (1981). Inhibition of purified human herpes simplex virus induced DNA polymerase by 9-(2-hydroxyethoxymethyl)guanine triphosphate: effects on primer template function. Journal of Biological Chemistry 256, 11447-51.
3. Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L. et al. (1987). The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. New England Journal of Medicine 317, 185-91.
4. de Clercq, E. (1998). The role of non-nucleosidic reverse transcriptase inhibitors (NNRTI) in the therapy of HIV-1 infections. Antiviral Research 38, 153-79.
5. Ruebsamen-Waigmann, H., Huguenel, E., Paessens, A., Kleim, J.-P., Wainberg, M. A. & Shah, A. (1997). Second-generation non-nucleosidic reverse transcriptase inhibitor HBY 097 and HIV-1 viral load. Lancet 394, 1517.
6. Huff, J. R. (1991). HIV protease: a novel chemotherapeutic target for AIDS. Journal of Medicinal Chemistry 34, 2305-14.
7. Wlodawer, A. & Erickson, J. W. (1993). Structure-based inhibitors of HIV-1 protease. Annual Review of Biochemistry 62, 543-85.
8. Lam, P. Y. S., Jadhav, P. K., Eyermann, C. J., Hodge, C. N., Ru, Y., Bacheler, L. T. et al. (1994). Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 263, 380-4.
9. Waxmann, L. & Darke, P. L. (2000). The herpesvirus proteases as targets for antiviral chemotherapy. Antiviral Chemistry and Chemotherapy 11, 219-32.
10. Arvin, A. M. & Alford, C. A. (1990). Chronic intrauterine and perinatal infections. In Antiviral Agents and Viral Diseases of Man, 3rd edn, (Galasso, G. J., Whitley, R. J. & Merigan, T. C., Eds), pp. 497-580. Raven Press, New York, NY.
11. de Jong, M. D., Galasso, G. J., Gazzard, B., Griffiths, P. D., Jabs, D. A., Kern, E. R. et al. (1998). Summary of the II International Symposium on Cytomegalovirus. Antiviral Research 39, 141-62.
12. Falagas, M. E., Paya, C., Ruthazer, R., Badley, A., Patel, R., Wiesner, R. et al. (1998). Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation - a prospective derivation and validation cohort analysis. Transplantation 66, 1020-8.
13. Jabs, D. A. (1995). Ocular manifestations of HIV infection. Transactions of the American Ophthalmological Society 93, 623-83.
14. Casado, J. L., Perez-Elias, M. J., Marti-Belda, P., Antela, A., Suarez, M., Ciancas, E. et al. (1998). Improved outcome of cytomegalovirus retinitis in AIDS patients after introduction of protease inhibitors. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 19, 130-4.
15. Torriani, F. J., Freeman, W. R., Macdonald, J. C., Karavellas, M. P., Durand, D. M., Jeffrey, D. D. et al. (2000). CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. AIDS 14, 173-80.
16. Jabs, D. A., Enger, C., Forman, M. & Dunn, J. P. (1998). Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. Antimicrobial Agents and Chemotherapy 42, 2240-4.
17. Jabs, D. A., Enger, C., Dunn, J. P. & Forman, M. (1998). Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. Journal of Infectious Diseases 177, 770-3.
18. Field, A. K. (1999). Human cytomegalovirus: challenges, opportunities and new drug development. Antiviral Chemistry and Chemotherapy 10, 219-32.
19. Sarasini, A., Baldanti, F., Furione, M., Percivalle, E., Brerra, R., Barbi, M. et al. (1995). Double resistance to ganciclovir and foscarnet of 4 human cytomegalovirus strains recovered from AIDS patients. Journal of Medical Virology 47, 237-44.
20. Harada, K., Eizuru, Y., Isashiki, Y., Ihara, S. & Minamishima, Y. (1997). Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir. Archives of Virology 142, 215-25.
21. Azad, R. F., Driver, V. B., Tanaka, K., Crooke, R. M. & Anderson, K. P. (1993). Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrobial Agents and Chemotherapy 37, 1945-54.
22. Underwood, M. R., Harvey, R. J., Stanat, S. C., Hemphill, M. L., Miller, T., Drach, J. C. et al. (1998). Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. Journal of Virology 72, 717-25.
23. Krosky, P. M., Underwood, M. R., Turk, S. R., Feng, K. W. H., Jain, R. K., Ptak, R. G. et al. (1998). Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. Journal of Virology 72, 4721-8.
24. Zacny, V. L., Gershburg, E., Davis, M. G., Biron, K. K. & Pagano, J. S. (1999). Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5,6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole. Journal of Virology 73, 7271-7.
25. Bender, W., Reefschlaeger, J., Eckenberg, P., Goldmann, S., Haerter, M., Hallenberger, S. et al. (1999). Patent Application WO 9937291, WO 9937608, WO 9937609; Priority January 23, 1998, DE 802437, DE 802436, DE 802439.
26. Eckenberg, P., Reefschlaeger, J., Bender, W., Goldmann, S., Haerter, M., Hallenberger, S. et al. (1999). Structure - activity relationships of BAY 38-4766 - a novel nonnucleosidic inhibitor of human cytomegalovirus replication. In Program and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 940, p. 321. American Society for Microbiology, Washington, DC.
27. Reefschlaeger, J., Bender, W., Eckenberg, P., Goldmann, S., Haerter, M., Hallenberger, S. et al. (1999). Antiviral activity and selectivity of BAY 38-4766 - a novel nonnucleosidic inhibitor of human cytomegalovirus replication. In Program and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 942, p. 321. American Society for Microbiology, Washington, DC.
28. Lamberti, C. & Weller, S. K. (1996). The herpes simplex virus type 1 UL6 protein is essential for cleavage and packaging but not for genomic inversion. Virology 226, 403-7.
29. Salmon, B. & Baines, J. D. (1998). Herpes simplex virus DNA cleavage and packaging: association of multiple forms of U(L)15-encoded proteins with B capsids requires at least the U(L)6, U(L)17, and U(L)28 genes. Journal of Virology 72, 3045-50.
30. Rao, V. B. & Black, L. W. (1988). Cloning, overexpression and purification of the terminase proteins gp16 and gp17 of bacteriophage T4: construction of a defined in vitro DNA packaging system using terminase proteins. Journal of Molecular Biology 200, 475-88.
31. Hallenberger, S., Trappe, J., Buerger, I., Bender, W., Eckenberg, P., Goldmann, S. et al. (1999). Mechanism of antiviral action of BAY 38-4766 - a novel nonnucleosidic inhibitor of human cytomegalovirus replication. In Program and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 941, p. 321. American Society for Microbiology, Washington, DC.
32. Buerger, I., Reefschlaeger, J., Bender, W., Eckenberg, P., Popp, A., Weber, D. et al. (2001). A novel non-nucleosidic inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. Journal of Virology 75, 9077-86.
33. McSharry, J. J., McDonough, A., Olsen, B., Hallenberger, S., Bender, W. et al. (2001). Comparison of drug susceptibilities of human cytomegalovirus (HCMV) clinical isolates for BAY 38-4766, BAY 43-9695, and ganciclovir. Antimicrobial Agents and Chemotherapy 45, 2925-7.
34. Weber, O., Bender, W., Eckenberg, P., Goldmann, S., Haerter, M., Hallenberger, S. et al. (2001). Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo. Antiviral Research 49, 179-89.
35. Witt-Laido, A., Beckermann, B., Schwarz, T., Steinke, W., Daehler, H., Henninger, K. et al. (1999). Pharmacokinetics in rat and dog of BAY 38-4766 - a novel nonnucleosidic inhibitor of human cytomegalovirus replication. In Program and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 944, p. 322. American Society for Microbiology, Washington, DC.
36. Kern, A. & Blombach, M. (1999). In vivo metabolism in rat and dog of BAY 38-4766 - a novel nonnucleosidic inhibitor of human cytomegalovirus replication. In Program and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 943, p. 322. American Society for Microbiology, Washington, DC.
37. Nagelschmitz, J., Moeller, J. G., Stass, H. H., Wadel, C. & Kuhlmann, J. (1999). Safety, tolerability, and pharmacokinetics of single oral doses of BAY 38-4766 - a novel nonnucleosidic inhibitor of human cytomegalovirus (HCMV) replication - in healthy male subjects. In Program and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 945, p. 322. American Society for Microbiology, Washington, DC.